Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,
and a comprehensive non-clinical data overview of the company’s lead SGT-003 program —

CHARLESTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present an oral presentation and six posters and at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, Baltimore, May 7-11.

The data presentations will focus on Solid Biosciences’ research and manufacturing capabilities aimed at advancing the field of gene therapy. They will cover various aspects of adeno-associated vector (AAV) manufacturing, novel capsid development, and non-clinical studies with a particular emphasis on the company's lead SGT-003 program.

"We are excited to share our latest scientific findings and advancements at the ASGCT Annual Meeting," said Bo Cumbo, President and Chief Executive Officer at Solid Biosciences. "Our presentations underscore our commitment to developing innovative therapies that address unmet medical needs in neuromuscular and cardiac diseases. We look forward to engaging with the gene therapy community and advancing the field together."

The presentations will feature advancements in gene therapy manufacturing, featuring novel mechanisms to enhance AAV production and refine purification methods. Additionally, innovative approaches in vector biology will be presented, leveraging in silico modeling for AAV vector design and showcasing capsid modifications for improved cardiac tissue targeting. Highlights from non-clinical studies of SGT-003 also will be shared, including findings on microdystrophin expression and functional efficacy in mouse models.

The presentations will cover key areas of Solid Biosciences' research and development initiatives, including:

Oral Presentation

A6 - AAV Vectors - Product Development Manufacturing and Approval Considerations

Novel Mechanism to Increase AAV Yield through Blocking AAV Transduction of Manufacturing HEK293 Cells During AAV Production

Lead Author: Xiaofei E

Abstract #28

May 7, 2:15-2:30pm ET

Poster Presentations

Process Development & Manufacturing

High-Throughput Workflows to Accelerate Development of Chromatographic Purification of rAAV Viral Vectors

Lead Author: Ryan DeGroot

Abstract 1543

May 10, 12:00-1:30pm ET